Aerocrine AB has announced that the company has entered into a distribution agreement with Chest M.I. Inc. to market and sell NIOX MINO, capable of enabling the fast and reliable management of airway inflammation and effective in the diagnosis, treatment and follow-up of asthma patients, throughout Japan.
Chest manufactures and sells a large range of products to measure lung function as well oxygen delivery systems for home use, and is one of the largest companies in its field with over 50% share of the Japanese market.
Chest will apply for market authorization of Aerocrine’s NIOX MINO in Japan and then proceed to product launch.
“Chest is an ideal partner for marketing and sales of our product in Japan,” said Paul de Potocki, CEO of Aerocrine.
... to continue reading you must be subscribed
